SCHEMBL24503315

SCHEMBL24503315

CCCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C/C(=C/NCCCCCNC(=O)CCC(=O)Oc2c(C)c(C)c3c(c2C)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O3)N=N)C(N)=O)CSCC(=O)NC(Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@H]2CC(N)=C3CC[C@@H](C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N4C[C@H](O)C[C@H]4C(=O)N[C@@H](Cc4c[nH]c5ccccc45)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc4csc5ccccc45)C(=O)N1C)N3C2=O

nearest known ligand 0.42

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 9/20 0.42
PDCD1 Q15116 7/20 0.42
NECTIN4 Q96NY8 2/20 0.36
CIB1 Q99828 3/20 0.35
TNFRSF9 Q07011 3/20 0.35
EPHA2 P29317 1/20 0.34
PRLHR P49683 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17751953 0.92 CD274 (0.51) CD274PDCD1NECTIN4CIB1TNFRSF9
SCHEMBL20009672 0.85 CD274 (0.52) CD274PDCD1NECTIN4CIB1TNFRSF9
SCHEMBL20013482 0.85 CD274 (0.51) CD274PDCD1NECTIN4CIB1TNFRSF9
SCHEMBL20010286 0.81 CD274 (0.44) CD274PDCD1CIB1EPHA2PRLHR
SCHEMBL17751983 0.81 CD274 (0.44) CD274PDCD1CIB1EPHA2PRLHR
SCHEMBL20013154 0.81 CD274 (0.43) CD274PDCD1NECTIN4CIB1TNFRSF9
SCHEMBL20013349 0.80 CD274 (0.49) CD274PDCD1CIB1EPHA2PRLHR
SCHEMBL21908407 0.80 CD274 (0.43) CD274PDCD1NECTIN4CIB1TNFRSF9
SCHEMBL17751984 0.80 CD274 (0.46) CD274PDCD1CIB1EPHA2PRLHR
SCHEMBL20013160 0.79 CD274 (0.42) CD274PDCD1NECTIN4CIB1TNFRSF9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11358988-B2 Immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2022-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11358988-B2 Immunomodulators CD74, ICOS, HAVCR2 CD274 36/4885PDCD1 79/4885NECTIN4 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.